NICE consultation on kidney cancer drugs

7 August, 2008

The National Institute for Health and Clinical Excellence has recommended that bevacizumab, sorafenib, sunitinib and temsirolimus should not be treatment options for advanced or metastatic renal cell carcinoma.

Register now for free to view this page

Please register now to access this content

This content is for registered users only

To check that you are registered please enter your email address below

Not registered?

Registration is simple and quick. By registering you will be able to read selected articles on HSJ.co.uk, PLUS sign up to HSJ email newsletters straight away.

Keep up to date. Sign up for regional email newsletters from HSJ Local

Practical solutions to today's key management challenges.

Visit the Resource Centre

Advertise with us

Advertise with HSJ, the UK’s leading health service management and policy title and reach an audience of senior health service management professionals via a variety of media solutions.

We provide a range of online advertising opportunities.
Subscribe to HSJ

As the essential resource on health management and policy, HSJ gives you invaluable insights to keep you up to speed with developments in the fast moving health service. Subscribe today and get complete access to hsj.co.uk, plus HSJ magazine
delivered to your door each week.
About HSJ

HSJ.co.uk and Health Service Journal are your source for NHS news and NHS jobs. Log on or subscribe to stay on top of health management and policy issues. From primary care commissioning to mental health, from policy making to the front line, HSJ offers unrivalled news, analysis and opinion.

HSJ has re-launched its jobs site. Search for a job, or set up a jobs email alert now!

Visit other EMAP sites

Select a site to visit

EDITOR'S COMMENT

NICE consultation on kidney cancer drugs

Register now for free to view this page

Newsletter Sign-up

Advertise with us

Subscribe to HSJ

About HSJ

Visit other EMAP sites